Clinical characteristics of COVID-19 patients treated with tocilizumab (TOC)
| Patient | Comorbidities | Organ Failure | Pre-TOC Inflammation Parameters | Post-TOC Inflammation Parameters | Outcome |
| 1 | None | Respiratory Cardiovascular | Ferritin 1933 ng/mL CRP 360 mg/L | Ferritin 1759 ng/mL CRP 154 mg/L | Deceased |
| 2* | Asthma Diabetes mellitus Hypertension Obesity | Respiratory Cardiovascular Renal | Ferritin 3504 ng/mL CRP 412 mg/L | N/A | Deceased |
| 3 | Splenectomy Hypertension | Respiratory | Ferritin 24, 203 ng/mL CRP 168 mg/L | Ferritin 3202 ng/mL CRP 40 mg/L | Alive |
| 4 | Diabetes Mellitus Hypertension Chronic Kidney Disease Obesity | Respiratory Renal | Ferritin 1730 ng/mL CRP 355 mg/L | Ferritin 356 ng/mL CRP 113 mg/L | Deceased |
| 5 | Hypertension | Respiratory Renal Cardiovascular | Ferritin 2006 ng/mL CRP 390 mg/L | Ferritin 933 ng/mL CRP 51 mg/L | Deceased |
| 6 | None | Respiratory Cardiovascular | Ferritin 1449 ng/mL CRP 376 mg/L | Ferritin 1353 ng/mL CRP 94 mg/L | Alive |
| 7† | Hypertension | Respiratory Cardiovascular | Ferritin 1386 ng/mL CRP 233 mg/L | Ferritin 1317 ng/mL CRP 75 mg/L | Alive |
| 8 | None | Respiratory Renal Cardiovascular | Ferritin 17, 810 ng/mL CRP 442 mg/L | Ferritin 18, 777 ng/mL CRP 164 mg/L | Deceased |
Organ failure listed is prior to TOC. Post-TOC inflammation parameters are after 72 hours unless otherwise stated.
*Patient only received one dose of tocilizumab as passed away prior to second dose.
†Patient received four doses of tocilizumab due to administrative error.
TOC, tocilizumab; I & V, intubation & ventilated; CRP, C-reactive peptide.